MAPT and Alzheimer disease: This is further supported by the fact that MAPT mutations (e.g. R406W) resulting in NFTs consisting of combined 3R and 4R tau (as seen in AD) do exhibit normal CSF p-tau181 and p-tau217 levels level when Aβ plaques are not present [56].